Evolent Health Q3 2020 Earnings Report
Key Takeaways
Evolent Health announced its Q3 2020 results, highlighting a 20.2% year-over-year revenue increase to $264.6 million. The company achieved an adjusted EBITDA of $12.7 million and reported a net loss attributable to common shareholders of $(37.3) million. Evolent Health also announced new provider and specialty care customer partnerships.
GAAP revenue increased by 20.2% year-over-year to $264.6 million.
Net loss attributable to common shareholders was $(37.3) million.
Adjusted EBITDA reached $12.7 million.
Approximately 3.5 million lives were on the platform.
Evolent Health
Evolent Health
Evolent Health Revenue by Segment
Forward Guidance
Evolent reiterated that it expects to be within previously-stated full year 2020 guidance ranges. For the three months ending December 31, 2020, Adjusted Revenue is expected to be in the range of approximately $249.0 million to $264.0 million. Adjusted EBITDA is expected to be in the range of approximately $10.0 million to $13.0 million.
Positive Outlook
- Adjusted Revenue for the year ending December 31, 2020 is expected to be in the range of approximately $1.000 billion to $1.014 billion.
- Adjusted Services revenue is forecasted to be approximately $903.3 million to $913.3 million.
- True Health premiums revenue is forecasted to be approximately $116.0 million to $120.0 million.
- Intersegment eliminations are forecasted to be approximately $(19.3) million for the full year.
- Adjusted EBITDA is expected to be in the range of approximately $35.0 million to $38.0 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income